CATALENT TO ACQUIRE DELPHI GENETICS
Neueste Ausführung ・ 23. Feb. 2021SOMERSET, N.J. and GOSSELIES, BELGIUM – February 23, 2021 — Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, and Delphi Genetics, a plasmid DNA (pDNA) cell and gene therapy contract development and manufacturing organization (CDMO) based in Gosselies, Belgium, today announced that they have entered into a final and definitive agreement whereby Catalent will acquire 100% of the shares of Delphi Genetics. Catalent is also announcing the launch of pDNA development and manufacturing services at its Rockville, Maryland facility. Together, the addition of pDNA technology and production capabilities marks a significant milestone for Catalent Cell & Gene Therapy. https://www.catalent.com/catalent-news/catalent-to-acquire-delphi-genetics-and-launch-us-plasmid-manufacturing-site-to-establish-global-pdna-development-and-manufacturing-capabilities/
